1750 related articles for article (PubMed ID: 16199422)
21. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
22. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
23. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.
Bonadonna G; Valagussa P; Tancini G; Rossi A; Brambilla C; Zambetti M; Bignami P; Di Fronzo G; Silvestrini R
NCI Monogr; 1986; (1):45-9. PubMed ID: 3534590
[TBL] [Abstract][Full Text] [Related]
24. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
25. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
27. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Hartman AR; Fleming GF; Dillon JJ
Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
[TBL] [Abstract][Full Text] [Related]
29. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
30. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
33. [Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
Shen K; Shen Z; Han Q
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):221-4. PubMed ID: 10920903
[TBL] [Abstract][Full Text] [Related]
34. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
[TBL] [Abstract][Full Text] [Related]
36. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
[TBL] [Abstract][Full Text] [Related]
37. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
[TBL] [Abstract][Full Text] [Related]
40. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
